To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 26, 2019___

Today's Rundown

Featured Story

La Jolla stops pivotal trial, parts company with CEO

La Jolla Pharmaceutical has stopped a pivotal trial of LJPC-401 after an interim review. The company disclosed the setback on the same day it revealed its CEO and president George Tidmarsh has left “to pursue other interests.”

Top Stories

CymaBay plummets 75% as it axes liver studies in NASH, PBC

CymaBay Therapeutics is pulling the plug on two midphase studies of its liver drug and putting all other studies of the drug on hold after biopsies found liver damage in some patients. The company’s stock nose-dived more than 75% Monday.

Teva forms academic R&D pacts to further biopharma strategy

Teva has entered into a pair of research collaborations with Israeli institutions. The Israeli pharma will support work on anti-cancer antibodies at the Weizmann Institute of Science while collaborating with Tel Aviv University on oncology and brain studies.

[Sponsored] How life sciences brands can win on mobile, right now

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

In conversation with Darren Kelly, CEO of Certa Therapeutics and OccuRx

At first glance, Darren Kelly doesn’t seem to sleep. He’s the CEO of not one but two fibrosis-related biotechs, an entrepreneur in residence at Australia’s largest life sciences-focused VC firm, a director at the Centre for Eye Research Australia and—to top it all off—the associate dean of innovation and enterprise at the University of Melbourne.

Attacking drug-resistant infections by exploiting bacterial weak spots

The world’s most vexing infectious bacteria are quickly becoming resistant to available antibiotics. Now, two research teams are proposing entirely new methods for attacking these bugs, not by killing them directly but rather by taking advantage of structural weaknesses in ways that make it impossible for the bacteria to survive.

AstraZeneca teams up with Novoheart for 'heart-in-a-jar'

We know about organs-on-a-chip; now, Big Pharma AstraZeneca is working with Canadian stem cell biotech Novoheart to develop a first-of-its-kind heart-in-a-jar.

Enrollment Showcase

Webinar, Dec. 3 | Precision Medicine Insights: Patient Safety

University of Florida precision medicine leaders highlight current knowledge and trends to advance the future of health care in this new webinar series. Register today.

Resources

[Q&A] Embarking Upon the Commercial Manufacturing Journey for a Biologic

In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey.

[Whitepaper] Modernizing clinical trials with Amazon Web Services (AWS)

From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks

[Whitepaper] Why Companies Leverage the Cloud to Smooth the Path to FDA Approval

See why visionaries outsource the design and management of the infrastructure allowing their scientists to innovate.

[Whitepaper] Medical Affairs 2025 Excellence in the Era of Precision Medicine

Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade.

[Whitepaper] The State of Real-World Evidence in Biopharma

This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow.

[Whitepaper] IBM Clinical Development: Key solutions for more efficient clinical research

IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology.

[Whitepaper] How Big is the US Market for Medical Devices and Technologies?

Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting.

[Whitepaper] The importance of early key opinion leader outreach in the biologics and biosimilars marketplace

Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more.

[Whitepaper] 5 Best Practices for Marketing Medical Devices

Discover solutions to the most common challenges faced by medical device companies.

[Whitepaper] The Impact of Step-Therapy Policies on Patients

Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system.

[Whitepaper] Q2 2019 Biopharma licensing report

18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights.

[Whitepaper] Synthesizing Success: Six Principles For Getting Pharmaceutical Development Right From The Start

Is your API development on track?

[Infographic] Implement the Patient Voice to Build an Effective Engagement App

Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app.

[eBook] Customer Experience: Shaping Digital Healthcare

Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve

[Whitepaper] How to succeed by failing faster

This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy.

[Whitepaper] Innovative Funding Models for Treatment of Cancer and Other High-Cost Chronic Noncommunicable Diseases

A global landscape study of funding trends and innovations.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

Events